EyePoint set for record drop after experimental eye drug misses study goal
EYPT•Next steps and peer reaction
EYPT sees data from a second late-stage wet AMD study in Q4 2026, and plans a potential FDA filing in H1 2027.
Shares of rival Ocular Therapeutix OCUL.O rise 8% to $10.79.
Including session's move, EYPT shares are down about 77% year to date, while OCUL is down about 11%.
Secondary analysis and treatment-burden data
An analysis excluding nine patients whose vision loss was unrelated to wet AMD shows Duravyu performed similarly to Eylea - EYPT.
Duravyu reduces treatment burden by 42% versus Eylea, or about two fewer injections through Week 56 - EYPT.
EYPT says 54% patients were supplement-free through week 56, and 79% received zero or one supplemental injection.
EyePoint shares tumble after Duravyu misses primary trial goal
Drug developer EyePoint's EYPT.O shares tumble 71% to $4.17, on track for their biggest one-day drop on record and lowest level since April 2025.
EYPT said experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss.
